Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine

The JAKoMo study, a 36-month, real-world analysis of 943 patients with myelofibrosis, showed that ruxolitinib provided rapid (≤ 6 months) and durable improvements in clinical outcomes and quality of life among patients who were ruxolitinib naive. Outcomes remained stable in ruxolitinib-experienced patients, and both groups reported an approximately 17% increase in patients experiencing a normal quality of life. Adverse events were fewer than in registrational trials, likely due to more conservative real-world dosing of ruxolitinib.